EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Title
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Principal Investigator
Pfaendler, Krista
Phase
II
Age Group
Adult
Applicable Disease Sites
Gynecologic Cancers
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417
Email:

View on ClinicalTrials.gov